People: BIOLASE Inc (BIOL.PH)

BIOL.PH on Philadelphia Stock Exchange

1.54USD
3 Sep 2015
Change (% chg)

-- (--)
Prev Close
$1.54
Open
--
Day's High
--
Day's Low
--
Volume
--
Avg. Vol
84
52-wk High
$2.90
52-wk Low
$1.41

Search Stocks

Summary

Name Age Since Current Position

Paul Clark

66 2014 Independent Chairman of the Board

Harold Flynn

50 2015 President, Chief Executive Officer

David Dreyer

58 2015 Chief Financial Officer

Brendan O'Connell

38 2015 Vice President - Finance and Corporate Controller

George Bickerstaff

59 2014 Director

Tamar Howson

66 2014 Director

Terence Kelly

53 2014 Director

Jonathan Lord

60 2014 Director

Frederic Moll

60 2013 Director

James Talevich

2013 Independent Director

Biographies

Name Description

Paul Clark

Mr. Paul Clark is Independent Chairman of the Board of the BIOLASE, INC. Mr. Clark served as Chairman, CEO, and President of ICOS Corporation, which was acquired by Lilly in 2007 for $2.2 billion. Previously, he was the President of Abbott's Pharmaceuticals Division. While at Abbott, sales grew from $250 million to $2.6 billion during his tenure as President. Mr. Clark received a B.A. in finance from the University of Alabama and an MBA from Dartmouth College.

Harold Flynn

Mr. Harold C. Flynn, Jr., is President and Chief Executive Officer of Biolase, Inc., effective July 13, 2015. Prior to joining the Company, Mr. Flynn has been President of Zimmer Dental, a leading manufacturer and provider of medical devices for the dental market including dental implants, prosthetics, and a range of other oral rehabilitation products. Previously, from 2004-2007, he was Divisional Vice President and General Manager at Abbott Hematology, a division of Abbott Laboratories. Mr. Flynn holds a Bachelor of Science degree in Electrical Engineering from the University of Maine at Orono. He holds patents in hematology and implantable devices for dentistry. He lives with his family in Encinitas, CA.

David Dreyer

Mr. David C. Dreyer CPA is Chief Financial Officer of Company., effective March 9, 2015. Mr. Dreyer has extensive experience as a Chief Financial Officer for a number of publicly-owned medical device, medical staffing and pharmaceutical companies. He also has hands-on experience in healthcare services, biotech/pharmaceutical and medical device research, manufacturing and marketing. Most recently, from 2010 to 2014, Mr. Dreyer was Chief Financial Officer of Irvine, CA-based Patient Safety Technologies Inc., a start-up public company that created a technology for preventing surgical retained sponge errors. While Mr. Dreyer was CFO, Patient Safety Technologies grew its revenues by 400 percent and its hospital customers five-fold in less than three years. Patient Safety Technologies was sold to Stryker in 2014. From 2009 to 2010, Mr. Dreyer was Chief Financial Officer of Ft. Lauderdale, FL-based Alphastaff Inc., the nation’s fourth largest professional employment outsourcing company. He implemented a system for the timely monitoring and reporting of financial results against goals establishing management accountability. While at Alphastaff, Mr. Dreyer also led the due diligence program and successful integration of that company’s first acquisition. Previously, from 2004 to 2009. Mr. Dreyer has also worked as a Chief Financial Officer at Sicor Inc. and Gensia Sicor Pharmaceutical and as the Financial Director of Elan Pharma-Athena Neurosciences. Mr. Dreyer has a Bachelor of Science degree in Accounting from Golden Gate University graduating Magna Cum Laude. He has been a Certified Public Accountant in California since 1986, and a member of the AICPA since 1987. Mr. Dreyer currently serves on the Boards of Directors of two public companies: InfuSystem, Inc. (NYSE MKT: INFU), and Dipl

Brendan O'Connell

Mr. Brendan O'Connell is appointed as Vice President - Finance and Corporate Controller in January 2015. Mr. O’Connell began his career with Biolase as our Assistant Controller in May 2007 and was promoted to serve as our Corporate Controller effective February 2009. Mr. O’Connell earned a Bachelor of Science in Accounting and an M.B.A. from University of California, Riverside.

George Bickerstaff

Mr. George W. Bickerstaff, III, is appointed as Director of Biolase Inc., effective June 16, 2014. Mr. Bickerstaff is currently a Managing Director of M.M. Dillon & Co., LLC, which he joined in 2005. Prior to joining M.M. Dillon & Co., LLC, Mr. Bickerstaff held various positions with Novartis International AG, a global pharmaceuticals and consumer health company, including Chief Financial Officer of Novartis Pharma AG from October 2000 to May 2005. From December 1999 to September 2000, Mr. Bickerstaff served as Executive Vice President and Chief Financial Officer of Workscape, Inc. a provider of employee-related information services. From July 1998 to December 1999, Mr. Bickerstaff served as Executive Vice President and Chief Financial Officer of Uniscribe Professional Services, Inc., a nationwide provider of paper and technology-based document management solutions. From January 1998 to June 1998, Mr. Bickerstaff served as Executive Vice President and Chief Financial Officer of Intellisource Group, Inc., a provider of information technology solutions to the federal, state and local government and utility markets. From July 1997 to December 1997, Mr. Bickerstaff served as Vice President of Finance of Cognizant Corporation, a global business information services company. From January 1990 to June 1997, Mr. Bickerstaff served in various senior finance roles, including Chief Financial Officer of IMS Healthcare, a global business information services company in the healthcare and pharmaceutical industries. Prior to that, Mr. Bickerstaff held various finance, audit and engineering positions with the Dun & Bradstreet Corporation and General Electric Company. Mr. Bickerstaff has been a member of the board of directors of CareDx, Inc., a company that develops, markets, and delivers diagnostic surveillance solutions for organ transplant recipients, since April 2014. Mr. Bickerstaff holds a B.S. in Engineering and a B.A. in Business Administration from Rutgers University (1978).

Tamar Howson

Ms. Tamar D. Howson is appointed as Director of Biolase Inc., effective June 16, 2014. She has served as an independent corporate business development and strategy consultant to life science companies since 2011. From 2009 to 2011, she provided business development support to life sciences companies as a member of the transaction team at JSB-Partners. From 2007 to 2008, Ms. Howson served as Executive Vice President, Corporate Business Development at Lexicon Pharmaceuticals. From 2001 to 2007, Ms. Howson served as Senior Vice President, Corporate and Business Development at Bristol-Myers Squibb. From 1991 to 2000, Ms. Howson served in various business development executive positions at SmithKline Beecham, including Senior Vice President and Director, Business Development. Ms. Howson also managed SmithKline Beecham’s venture capital fund, SR-One. Prior to that, Ms. Howson served in various business development, investment, and engineering positions at Johnston Associates, Squibb Corporation, FMC Corporation, and Envirotech Corporation. Ms. Howson currently serves on the board of directors of the following publicly traded companies: Actavis plc, Idenix Pharmaceuticals Inc., OXiGENE, Inc., and Organovo Holdings, Inc. Additionally, she is a director of the International Partnership for Microbicides, a non-profit product development organization. Ms. Howson was previously a member of board of directors of the following publicly traded corporations: Warner Chilcott plc from May 2013 until she joined the board of directors of Actavis plc in October 2013; Aradigm Corporation from November 2010 to April 2013; Soligenix, Inc. from September 2010 to January 2013; and BioLineRx Ltd. from August 2007 to June 2009. Ms. Howson holds an MBA from Columbia University (1980), an M.S. in Chemical Engineering from the City College of New York (1976), and a B.S. in Chemical Engineering from Technion - Israel Institute of Technology (1973).

Terence Kelly

Dr. Terence A. Kelly, Ph.D., is appointed as Director of Biolase Inc., effective June 16, 2014. He has over 20 years of experience as a scientist and executive in the pharmaceutical industry starting as a medicinal chemist in 1990. Dr. Kelly is currently the President and Chief Executive Officer of CoMentis, Inc., a venture-backed private biotech company focused on neurodegenerative diseases, and a founder of Kelly Pharma Research Consulting, LLC. From 1990 to 2009, Dr. Kelly served in various scientific and executive positions at Boehringer Ingelheim, where after a successful early career developing LFA-1 antagonists, he led its US-based medicinal chemistry department, which included 145 scientists in the high throughput screening, computational chemistry, structural biology, combinatorial chemistry and medicinal chemistry groups. Dr. Kelly holds a B.S. degree in Chemistry at Rensselaer Polytechnic Institute (1982) and a Ph.D. degree in Chemistry at the University of Texas at Austin (1988). He completed postdoctoral work in natural products synthesis at Yale University (1988-1990) and holds an MBA from New York University, Stern School of Business (1998). Dr. Kelly is the co-author of over 25 scientific publications and serves on the College of Natural Sciences Advisory Council for the University of Texas.

Jonathan Lord

Frederic Moll

Dr. Frederic H. Moll, M.D., has been appointed as Director of BIOLASE, Inc., effective June 7, 2013. Frederic Moll, M.D., is Chairman and Chief Executive Officer of Auris Surgical Robotics, Inc., the fourth surgical robotics company he has founded. In 1995, Dr. Moll co-founded Intuitive Surgical, Inc. (NASDAQ: ISRG). He served as Intuitive's CEO through 1996 and a Director through 2004. Many credit Dr. Moll with creating the surgical robotics industry. Dr. Moll has been appointed to serve as a member of the Compensation Committee of the Board. Prior to Intuitive Surgical, Inc., Dr. Moll founded Endotherapeutics, which was acquired by U.S. Surgical in 1992. He co-founded Origin Medsystems, Inc., which was also acquired in 1992 by Eli Lilly and later became an operating company in Guidant Corporation. Dr. Moll served as medical director of Guidant's surgical device division from 1992 to 1995. Before co-founding Origin Medsystems, Dr. Moll invented the safety trocar, which many experts believe created modern general laparoscopic surgery. He also co-founded the intravascular robotics company, Hansen Medical, Inc. and is a Director of the hard-tissue orthopedics robotics company, MAKO Surgical Corporation.

James Talevich

Mr. James R. Talevich is Independent Director of the Company. Mr. Talevich currently serves on the board of directors of Nova LifeStyle, Inc. (STVS.PK), an international manufacturing company. Mr. Talevich currently serves as a member of the Executive Committee and Advisory Council of the SEC Financial Reporting Institute at the USC Marshall School of Business, and as a member of the UCLA Anderson School of Management Alumni Board of Directors. Prior to his current roles, he served as Chief Financial Officer of I-Flow Corporation, a NASDAQ-listed medical technology company, from 2000 to 2009, Chief Financial Officer of Tectrix Fitness Equipment Inc. from 2005 to 2009, and Chief Financial Officer of Gish Biomedical, Inc., a NASDAQ-listed manufacturing company, from 1999 to 2000. From 2008 to 2009, he served on the Board of Directors of AcryMed, Inc., a developer of antimicrobial nanoparticle technologies. Mr. Talevich received a B.A. in physics from California State University, Fullerton, and an MBA from the UCLA Anderson School of Management. He is licensed as a Certified Public Accountant. There are no understandings or arrangements between Mr. Talevich or any other person and the Company or any of its subsidiaries pursuant to which Mr. Talevich was selected to serve as a director of the Company. There are no family relationships between Mr. Talevich and any director, executive officer or person nominated or chosen by the Company to become a director or executive officer, and there are no transactions between Mr. Talevich or any of his immediate family members and the Company or any of its subsidiaries.
Search Stocks